1. Home
  2. ASMB vs JVSA Comparison

ASMB vs JVSA Comparison

Compare ASMB & JVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • JVSA
  • Stock Information
  • Founded
  • ASMB 2005
  • JVSA 2021
  • Country
  • ASMB United States
  • JVSA Hong Kong
  • Employees
  • ASMB N/A
  • JVSA N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • JVSA
  • Sector
  • ASMB Health Care
  • JVSA
  • Exchange
  • ASMB Nasdaq
  • JVSA NYSE
  • Market Cap
  • ASMB 84.5M
  • JVSA 80.7M
  • IPO Year
  • ASMB 2010
  • JVSA 2024
  • Fundamental
  • Price
  • ASMB $12.48
  • JVSA $10.58
  • Analyst Decision
  • ASMB Buy
  • JVSA
  • Analyst Count
  • ASMB 2
  • JVSA 0
  • Target Price
  • ASMB $35.00
  • JVSA N/A
  • AVG Volume (30 Days)
  • ASMB 23.1K
  • JVSA 28.5K
  • Earning Date
  • ASMB 03-27-2025
  • JVSA 01-01-0001
  • Dividend Yield
  • ASMB N/A
  • JVSA N/A
  • EPS Growth
  • ASMB N/A
  • JVSA N/A
  • EPS
  • ASMB N/A
  • JVSA 0.24
  • Revenue
  • ASMB $28,326,000.00
  • JVSA N/A
  • Revenue This Year
  • ASMB $282.16
  • JVSA N/A
  • Revenue Next Year
  • ASMB N/A
  • JVSA N/A
  • P/E Ratio
  • ASMB N/A
  • JVSA $43.72
  • Revenue Growth
  • ASMB N/A
  • JVSA N/A
  • 52 Week Low
  • ASMB $11.05
  • JVSA $10.02
  • 52 Week High
  • ASMB $19.93
  • JVSA $10.64
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 37.42
  • JVSA N/A
  • Support Level
  • ASMB $12.10
  • JVSA N/A
  • Resistance Level
  • ASMB $13.25
  • JVSA N/A
  • Average True Range (ATR)
  • ASMB 0.58
  • JVSA 0.00
  • MACD
  • ASMB -0.10
  • JVSA 0.00
  • Stochastic Oscillator
  • ASMB 14.79
  • JVSA 0.00

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About JVSA JVSPAC ACQUISITION CORP

JVSPAC Acquisition Corp is blank check company.

Share on Social Networks: